Introduction
============

Gastric cancer (GC) is a very common malignant tumor throughout the world, and it leads to cancer-related mortality rates that are higher than those of many other tumors.[@b1-ott-10-3145] Although efforts toward early diagnoses and treatment for GC have made great progress, and we can frequently perform radical surgery for GC, the prognoses for patients with advanced GC are still very poor, and their 5-year survival rate remains in an unsatisfactory range of 10%--15%.[@b2-ott-10-3145] To improve the treatment of GC patients, developing prognostic indicators is critical for improving therapeutic decision-making.

Several lines of research have reported that the immune system plays a crucial role in controlling tumor growth, and neutrophils, lymphocytes, monocytes, and platelets are important for the tumor-induced systemic inflammatory response (SIR).[@b3-ott-10-3145],[@b4-ott-10-3145] The SIR may accelerate tumor development and distant metastases through several mechanisms, such as promoting secretion of inflammatory mediators and cytokines, inhibiting the apoptosis, and damaging the DNA of tumor cells.[@b5-ott-10-3145] Biochemical markers, neutrophils, lymphocytes, monocytes, and platelets can be used to evaluate the host antitumor immune responses and effectively predict cancer prognoses.[@b3-ott-10-3145]

In addition, some reports indicate that a "prognostic nutritional index" (PNI) derived from preoperative blood is a gauge of nutritional status that is also associated with the mortality of GC patients.[@b6-ott-10-3145] In this study, we sought clinicopathological characteristics that affected these biomarkers and investigated the relationship of these biochemical markers to the survival of GC patients.

Materials and methods
=====================

Patients
--------

A total of 1,990 consecutive patients with histologically proven GC patients, aged 19--88 (mean age: 62 years), were recruited as subjects for this study. They had gastrectomies performed in the Harbin Medical University Cancer Hospital (Heilongjiang, People's Republic of China) between January 2007 and December 2011. All of these patients had preoperative pathological diagnoses through electronic gastroscopies, and the pathological staging was based on the 7th edition of the TNM-classification given by the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC). Patients were not allowed to eat or drink after 10 PM on the first day they were admitted to hospital, and blood samples were acquired before 6 AM the next day and sent to the clinical laboratory for immediate analysis of standard clinical tests. The inclusion criteria were as follows: 1) All patients who underwent total or subtotal gastrectomy, 2) radical surgery (R0 with clear margins) patients underwent D2^+^ lymph nodes resection, while R1 or R2 surgery patients (with residual cancer postoperatively) did not. 3) None of these patients received preoperative neoadjuvant chemotherapy, radiotherapy, or any other antitumor therapies. 4) None of these patients died during a perioperative and a postoperative follow-up time that was longer than 2 months. 5) None of these patients received transfusions before blood tests and none were infected. 6) All of the patients died of GC or GC-related diseases. 7) All of the patients signed written informed consent on the day they were admitted to the hospital to allow the use of their data for any future study. The research project was approved by the Medical Ethics Committee of the Harbin Medical University Cancer Hospital. The clinical characteristics of the 1,990 study subjects with GC are summarized in [Table 1](#t1-ott-10-3145){ref-type="table"}.

Patients underwent relevant investigation 1 week before surgery. All patients recruited with stage IV cancer were confirmed by pathology of their liver, lung, or peritoneal metastases and complications such as bleeding, perforation, and pyloric obstruction. The standard blood tests obtained on the morning after admission included albumin (g/L), white blood cell count (10^9^/L), neutrophil count (10^9^/L), lymphocyte count (10^9^/L), monocyte count (10^9^/L), platelet count (10^9^/L), carbohydrate antigen 19-9 (CA19-9) (U/mL), and carcinoembryonic antigen (CEA) (ng/mL). The neutrophil to lymphocyte ratio (NLR), derived neutrophil to lymphocyte ratio (dNLR), monocyte to lymphocyte ratio (MLR), platelet to lymphocyte ratio (PLR), and prognostic nutritional index (PNI) were calculated using the following formulas:[@b7-ott-10-3145]--[@b9-ott-10-3145] NLR = Neutrophil count/Lymphocyte count;dNLR = Neutrophil count/(White blood cell count - Neutrophil count);MLR = Monocyte count/Lymphocyte count;PLR = Platelet count/Lymphocyte count;PNI = Albumin count + Lymphocyte count × 5.

Patient follow-up
-----------------

Every patient was followed up regularly until June 2016 or death (In the first 2 postoperative years, it was every 3 months, and in the following several years it was at 6 months intervals). The total duration of follow-up varied from 3 months to 9 years, with a median of 37 months. Overall survival time was calculated as the interval from the surgery to death.

Statistical analysis
--------------------

The optimal cut-off levels for NLR, dNLR, MLR, and PLR were determined by receiver operating curve (ROC) analysis.[@b10-ott-10-3145],[@b11-ott-10-3145] As the optimal cut-off level for PNI did not have statistical significance, we took the average PNI value (51.07) as the cut-off point ([Table 2](#t2-ott-10-3145){ref-type="table"}, [Figure 1](#f1-ott-10-3145){ref-type="fig"}). *χ*^2^ tests were used to compare and assess the association between NLR, dNLR, MLR, PLR, and PNI and the subjects' clinicopatho-logical characteristics. Survival curves were calculated by the Kaplan--Meier method, and the equivalences of survival curves were analyzed using the log-rank test. Multivariate analysis was evaluated by Cox proportional hazards model, and all of the significant characteristics in univariate analysis were carried into multivariate analysis. A *P*\<0.05 was considered statistically significant. All of the statistical analyses were performed using SPSS version 17.0 (IBM Corp., Armonk, NY, USA).

Results
=======

The relationship between clinicopathological characteristics and biomarkers
---------------------------------------------------------------------------

We calculated the contrasts between the higher and lower biomarker levels of NLR, dNLR, MLR, PLR, and PNI to study the relationship between the different patients' clinic-pathological characteristics and biomarkers ([Table 3](#t3-ott-10-3145){ref-type="table"}). We found that NLR was significantly associated with age, tumor invasion (T), lymph nodes metastasis (N), distant metastasis, TNM stage, surgical radicality, tumor size, metastatic lymph node ratio (MLNR), ascites, CEA, CA19-9, and Hb. dNLR was significantly associated with age, lymph nodes metastasis, distant metastasis, stage, radicality, tumor size, MLNR, ascites, CEA, CA19-9, and Hb. MLR was significantly associated with sex, age, tumor invasion, lymph nodes metastasis, distant metastasis, TNM stage, radicality, tumor size, MLNR, ascites, CEA, CA19-9, and Hb. PLR was significantly associated with sex, tumor invasion, lymph nodes metastasis, distant metastasis, TNM stage, radicality, tumor size, MLNR, ascites, CEA, CA19-9, Hb, and smoking. PNI was significantly associated with tumor invasion, lymph nodes metastasis, distant metastasis, TNM stage, radicality, tumor size, MLNR, ascites, and Hb.

Thus, these tumor-related factors such as lymph node metastases, distant metastasis, AJCC TNM stage, radicality, tumor size, MLNR, ascites, and Hb were all significantly associated with NLR, dNLR, MLR, PLR, and PNI.

The relationship between biomarkers, clinicopathological characteristics, and clinical prognosis
------------------------------------------------------------------------------------------------

The results revealed that age (\>62 years), deeper tumor invasion, more lymph nodes with metastatic involvement, distant metastasis, advanced TNM stage, an R1 or R2 resection (without "clean margins" and leaving residual tumor), larger tumor size (\>6 cm), upper tumor location, higher MLNR (\>31.5%), undifferentiated neoplasms, ascites, higher CA19-9 levels (\>37 U/mL), higher CEA (\>5 ng/mL), lower Hb (≤130 g/L), NLR (\>2.10), dNLR (\>1.73), MLR (\>0.22), PLR (\>139.12), and PNI (≤51.07) were significantly connected with reduced overall survival time in univariate Kaplan--Meier analyses and log-rank tests ([Table 4](#t4-ott-10-3145){ref-type="table"}, [Figure 2](#f2-ott-10-3145){ref-type="fig"}). The significant factors in the univariate Kaplan--Meier analyses were further studied in multivariate Cox regression model, and our results indicated that age, tumor depth, the number of metastatic lymph nodes, distant metastasis, AJCC TNM stage, radicality, tumor size, MLNR, differentiation, CA19-9, CEA, dNLR, and MLR were significantly associated with overall survival time (*P*\<0.05 for all). Thus, dNLR and MLR were independent risk factors for overall survival time ([Table 4](#t4-ott-10-3145){ref-type="table"}).

Then, as the long-term clinical outcomes of dNLR (*P*\<0.001) and MLR (*P*\<0.001) were similar to each other, we tried to study the prognostic value of dNLR and MLR combined together in the whole cohort. We hypothesized that patients with dNLR \>1.73 and MLR \>0.22 had scores of 2, and dNLR ≤1.73 and MLR ≤0.22 had scores of 0. Patients with dNLR \>1.73 and MLR ≤0.22 or dNLR ≤1.73 and MLR \>0.22 had score of 1. [Figure 3](#f3-ott-10-3145){ref-type="fig"} showed that the overall survival time decreased as the scores increased. We thus found that dNLR combined with MLR could perfectly predict prognoses (*P*\<0.001). Finally, we analyzed the prognostic value of dNLR, MLR, and their combination scores when patients were divided by the AJCC TNM stage. The biomarker dNLR was significant in stages III (*P*=0.001) and IV (*P*=0.004), but not in stages I (*P*=0.263) and II (*P*=0.676). MLR was significant in stages I (*P*=0.038) and III (*P*=0.010), but not in stages II (*P*=0.208) and IV (*P*=0.067); the combination score was significant in stages III (*P*=0.001) and IV (*P*=0.015), but not in stages I (*P*=0.165) and II (*P*=0.484) ([Figure 4](#f4-ott-10-3145){ref-type="fig"}).

Discussion
==========

Pietrzyk et al[@b12-ott-10-3145] reported that hematological parameters such as NLR and PLR could be used to discriminate GC patients from non-GC patients. It was also reported that SIR had a close relationship with the prognoses of many tumors.[@b13-ott-10-3145] Inflammation could promote cellular proliferation in neoplasms, stimulate angiogenesis, and lead to lower immunity, thus promoting cancer progression and distant metastases of tumors.[@b14-ott-10-3145] Many clinical studies have shown that the occurrence and development of GC is closely linked with a chronic SIR.[@b7-ott-10-3145],[@b15-ott-10-3145],[@b16-ott-10-3145] SIR was also reported to be correlated with chemotherapy responses in patients with unresectable GC.[@b17-ott-10-3145] A few studies showed that PNI as a nutritional status indicator was helpful in predicting survival of patients with GC and many other tumors.[@b9-ott-10-3145],[@b18-ott-10-3145],[@b19-ott-10-3145]

A higher NLR, dNLR, MLR, PLR, or lower PNI means elevated neutrophils, monocytes, and platelets or decreased lymphocytes and serum albumin. Neutrophils can secret VEGF (vascular endothelial growth factor), ROS (reactive oxygen species), NO (nitric oxide), interleukin-18, and matrix metalloproteinase and can suppress the tumor-induced T-cell response that promotes tumorigenesis, growth, and metastasis.[@b20-ott-10-3145] Platelets can accelerate tumor growth by secreting VEGF, which then promotes angiogenesis.[@b21-ott-10-3145] Lymphocytes, especially CD3^+^ T-cells, CD8^+^ T-cells, and NK cells, can inhibit tumorigenesis and kill tumor cells efficiently. A decreased lymphocyte count leads to a decreased anti-tumor response.[@b22-ott-10-3145],[@b23-ott-10-3145] Macrophages originating from monocytes can devour tumor cells. This anticancer activity can be augmented when chemokines stimulated by the tumor microenvironment promote macrophage chemotaxis to the neoplastic tissues.[@b24-ott-10-3145] While albumin levels are used to assess nutritional status and immune function, lower albumin is associated with tumor progression, metastasis, and higher risk of death after surgery.[@b25-ott-10-3145]

Of the clinical factors such as metastatic lymph nodes, distant metastasis, AJCC TNM stage, radical resection, tumor size, MLNR, ascites, and Hb that affect NLR, dNLR, MLR, PLR, and PNI simultaneously, only ascites and Hb were not independent prognostic factors for overall survival. This may suggest that bleeding can lead to increased white blood cell counts and albumin loss that is similar to inflammation and malnutrition, but that this phenomenon was different from the SIR that accompanied tumor appearance and growth. The five biomarkers (NLR, dNLR, MLR, PLR, and PNI) monitored preoperatively in the blood of GC patients have close relationship with the prognoses and overall survival of the patient. Higher NLR, dNLR, MLR, and PLR and lower PNI predicted shorter survival time for GC patients with resectable neoplastic lesions. We have no definite mechanisms to explain these observations, although it has been suggested that this result may be related to the immune microenvironment of the tumor cells.[@b5-ott-10-3145],[@b26-ott-10-3145]

Our findings for NLR, dNLR, MLR, PLR, and PNI are all derived from routine peripheral blood results of preoperative patients, and they are simple and convenient to use for predicting the prognoses and survival of tumor patients. The GC patients need no additional costly investigations to obtain these risk indicators. However, in our study only dNLR and MLR were independent risk factors for overall survival in the Cox multivariate analysis. Kim et al[@b27-ott-10-3145] found that NLR was a better indicator than PLR for predicting overall survival. Sakurai et al[@b9-ott-10-3145] found that PNI was effective for predicting overall survival in elderly and stage I GC patients after gastrectomy. In contrast, our present results failed to confirm the prognostic value of NLR, PLR, and PNI in a Cox multivariate analysis. At the same time, we found that dNLR, MLR, and their combination scores were mainly statistically significant in later stages (III and IV), but not in earlier stages of GC, and the combination scores we derived did not show superior results over dNLR or MLR separately. In spite of this, the SIR may still have been becoming more intense as the tumors progressed, but was not obvious in the initial stages. However, further investigations will be needed to illuminate this phenomenon.

A few limitations of this research should be reviewed. First, this was a retrospective study in a single institution, and some patients were lost to follow-up. Second, GC patients with III/IV stage disease account for 68% of the study population, which may influence the results. Third, some patients with factors such as vascular invasion and postoperative adjuvant chemotherapy, which may affect prognoses to a large extent, were not enrolled according to the study criteria. Therefore, further research will be needed to clarify the relationship between the inflammatory biomarkers and the prognosis of GC patients.

Conclusion
==========

In summary, preoperative NLR, dNLR, MLR, PLR, and PNI in peripheral blood proved to be significant prognostic indicators of the postoperative course of GC patients. Moreover, dNLR and MLR are independent prognostic factors for overall survival and may be better biomarkers in predicting overall survival of patients with GC, especially those with advanced stages of disease. A broad range of institutions should be organized to perform a multicenter study on the prognostic significance of these indicators. Perhaps, in countries like China, which have less developed economies, these readily available and inexpensive biomarkers can be developed to better predict GC prognoses and guide more effective therapeutic strategies.
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![Kaplan--Meier curves for overall survival according to NLR, dNLR, MLR, PLR, and PNI.\
**Abbreviations:** dNLR, derived neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PNI, prognostic nutritional index.](ott-10-3145Fig2){#f2-ott-10-3145}

![Kaplan--Meier curves for overall survival according to scores of dNLR and MLR.\
**Abbreviations:** dNLR, derived neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio.](ott-10-3145Fig3){#f3-ott-10-3145}

###### 

Overall survival stratified by TNM stage of dNLR, MLR, and their combination score. A, D, G, and J were stages I, II, III, and IV of dNLR, respectively; B, E, H and K were stages I, II, III, and IV of MLR, respectively; C, F, I, and L were stages I, II, III, and IV of their combination scores.

**Abbreviations:** dNLR, derived neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio.
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###### 

Characteristic of GC patients

  Variable                                                     N (%)
  ------------------------------------------------------------ --------------
  Sex                                                          
   Female                                                      523 (26.3)
   Male                                                        1,467 (73.7)
  Age (year)                                                   
   ≤62                                                         1,232 (61.9)
   \>62                                                        758 (38.1)
  Tumor depth                                                  
   T1                                                          124 (6.2)
   T2                                                          187 (9.4)
   T3                                                          512 (25.7)
   T4                                                          1,167 (58.7)
  Lymph nodes                                                  
   N0                                                          460 (23.1)
   N1                                                          343 (17.2)
   N2                                                          447 (22.5)
   N3                                                          740 (37.2)
  Metastasis                                                   
   M0                                                          1,781 (89.5)
   M1                                                          209 (10.5)
  AJCC stage                                                   
   I                                                           162 (8.1)
   II                                                          476 (23.9)
   III                                                         1,143 (57.5)
   IV                                                          209 (10.5)
  Radicality                                                   
   R0                                                          1,468 (73.8)
   R1 or R2                                                    522 (26.2)
  Tumor size (cm)                                              
   ≤6                                                          1,290 (64.8)
   \>6                                                         700 (35.2)
  Location                                                     
   Upper                                                       273 (13.7)
   Middle                                                      371 (18.6)
   Low                                                         1,160 (58.3)
   Whole                                                       186 (9.4)
  MLNR[a](#tfn1-ott-10-3145){ref-type="table-fn"}              
   ≤31.5%                                                      1,155 (58.0)
   \>31.5%                                                     835 (42.0)
  Differentiation[b](#tfn2-ott-10-3145){ref-type="table-fn"}   
   Differentiated                                              322 (16.2)
   Undifferentiated                                            1,668 (83.8)
  Ascites                                                      
   No                                                          1,912 (96.1)
   Yes                                                         78 (3.9)
  CA19--9 (U/mL)                                               
   ≤37                                                         1,556 (78.2)
   \>37                                                        434 (21.8)
  CEA (ng/mL)                                                  
   ≤5                                                          1,527 (76.7)
   \>5                                                         463 (23.3)
  Hb (g/L)                                                     
   ≤130                                                        1,014 (51.0)
   \>130                                                       976 (49.0)
  Tobacco                                                      
   Yes                                                         985 (49.5)
   No                                                          1,005 (50.5)
  dNLR                                                         
   ≤1.73                                                       1,206 (60.6)
   \>1.73                                                      784 (39.4)
  MLR                                                          
   ≤0.22                                                       917 (46.1)
   \>0.22                                                      1,073 (53.9)
  NLR                                                          
   ≤2.10                                                       1,018 (51.2)
   \>2.10                                                      972 (48.8)
  PLR                                                          
   ≤139.12                                                     908 (45.6)
   \>139.12                                                    1,082 (54.4)
  PNI                                                          
   ≤51.07                                                      960 (48.2)
   \>51.07                                                     1,030 (51.8)

**Notes:**

The average point of MLNR was 31.5%.

Grades1 and 2 were differentiated, and grades 3 and 4 were undifferentiated.

**Abbreviations:** AJCC, American Joint Committee on Cancer; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; dNLR, derived neutrophil to lymphocyte ratio; GC, gastric cancer; Hb, hemoglobin; MLNR, Metastatic lymph nodes ratio; MLR, monocyte to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PNI, prognostic nutritional index.

###### 

The optimal cut-off point for overall survival

  Variables   AUC     Cut-off point   *P*-value
  ----------- ------- --------------- -----------
  NLR         0.555   2.10            \<0.001
  dNLR        0.551   1.73            \<0.001
  MLR         0.554   0.22            \<0.001
  PLR         0.576   139.12          \<0.001
  PNI         0.395   --              \<0.001

**Note:** '--' indicates no appropriate cut-off point.

**Abbreviations:** AUC, area under the curve; NLR, neutrophil to lymphocyte ratio; dNLR, derived neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PNI, prognostic nutritional index.

###### 

Relationship between clinicopathological characteristics and NLR, dNLR, MLR, PLR, and PNI

  Factors             NLR   dNLR     MLR       PLR     PNI                                                                                    
  ------------------- ----- -------- --------- ------- -------- --------- ----- --------- --------- ----- --------- --------- ----- --------- ---------
  Sex                                0.075                      0.143                     0.001                     \<0.001                   0.943
   Male               733   3.163              875     2.143              643   11.368              706   14.032              707   0.005     
   Female             285                      331                        274                       202                       253             
  Age (year)                         0.01                       0.043                     \<0.001                   0.066                     0.389
   ≤62                658   6.572              768     4.076              610   15.338              582   3.388               585   0.743     
   \>62               360                      438                        307                       326                       375             
  Tumor depth                        \<0.001                    0.051                     0.001                     \<0.001                   \<0.001
   T1                 79    22.075             83      7.753              75    16.178              84    49.662              36    44.861    
   T2                 118                      127                        90                        112                       60              
   T3                 254                      309                        249                       233                       265             
   T4                 567                      687                        503                       479                       599             
  Lymph nodes                        \<0.001                    0.025                     0.003                     \<0.001                   \<0.001
   N0                 251   21.328             286     9.339              234   14.14               243   25.644              185   30.762    
   N1                 188                      221                        159                       169                       159             
   N2                 250                      282                        221                       209                       203             
   N3                 329                      417                        303                       287                       413             
  Metastasis                         \<0.001                    0.001                     \<0.001                   \<0.001                   \<0.001
   M0                 944   23.181             1,101   10.505             855   25.326              837   12.791              831   16.998    
   M1                 74                       105                        62                        71                        129             
  AJCC stages                        \<0.001                    0.003                     \<0.001                   \<0.001                   \<0.001
   I                  100   31.239             105     13.677             91    32.253              103   43.485              47    46.379    
   II                 263                      307                        238                       246                       206             
   III                581                      689                        526                       488                       578             
   IV                 74                       105                        62                        71                        129             
  Radicality                         \<0.001                    \<0.001                   \<0.001                   \<0.001                   \<0.001
   R0                 815   42.615             943     30.955             728   27.764              743   56.056              638   51.226    
   R1 or R2           203                      263                        189                       165                       322             
  Tumor size (cm)                    \<0.001                    \<0.001                   \<0.001                   \<0.001                   \<0.001
   ≤6                 736   51.064             840     31.287             640   18.413              680   74.203              521   90.59     
   \>6                282                      366                        277                       228                       439             
  Location                           0.223                      0.644                     0.14                                                
   Upper              140   4.38               170     1.667              108   5.479               128   4.232     0.237     119   4.223     0.238
   Middle             172                      215                        175                       158                       187             
   Low                610                      705                        548                       546                       557             
   Whole              96                       116                        86                        76                        97              
  MLNR                               \<0.001                    \<0.001                   \<0.001                   \<0.001                   \<0.001
   ≤31.5%             652   30.88              744     16.758             579   18.167              588   30.943              502   25.167    
   \>31.5%            366                      462                        338                       320                       458             
  Differentation                     0.876                      0.31                      0.68                      0.992                     0.351
   Differentiated     166   0.024              187     1.029              145   0.17                147   \<0.001             163   0.871     
   Undifferentiated   852                      1,019                      772                       761                       797             
  Ascites                            \<0.001                    \<0.001                   0.038                     \<0.001                   \<0.001
   No                 996   17.114             1,176   16.669             890   4.295               892   20.641              904   18.037    
   Yes                22                       30                         27                        16                        56              
  CA19--9 (µ/mL)                     0.005                      0.045                     0.017                     \<0.001                   0.17
   ≤37                822   7.982              961     4.007              739   5.735               742   12.183              738   1.884     
   \>37               196                      245                        178                       166                       222             
  CEA (ng/mL)                        \<0.001                    0.005                     0.017                     0.007                     0.216
   ≤5                 824   20.685             951     7.721              726   5.66                722   7.238               725   1.528     
   \>5                194                      255                        191                       186                       235             
  Hb (g/L)                           \<0.001                    \<0.001                   \<0.001                   \<0.001                   \<0.001
   ≤130               435   56.404             545     40.697             399   25.326              280   270.452             644   193.062   
   \>130              583                      661                        518                       628                       316             
  Tobacco                            0.537                      0.201                     0.992                     0.001                     0.665
   Yes                497   0.381              583     1.636              454   \<0.001             488   12.05               480   0.187     
   No                 521                      623                        463                       420                       480             

**Abbreviations:** AJCC, American Joint Committee on Cancer; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; dNLR, derived neutrophil to lymphocyte ratio; Hb, hemoglobin; MLNR, metastatic lymph node ratio; MLR, monocyte to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PNI, prognostic nutritional index.

###### 

Univariate and multivariate analysis of factors for overall survival

  Factors              Univariate   Multivariate           
  -------------------- ------------ ---------------------- ---------
  Sex                  0.836                               
  Age (year)           \<0.001      1.196 (1.071--1.336)   0.002
  Tumor depth          \<0.001      1.181 (1.066--1.308)   0.001
  Lymph nodes          \<0.001      1.215 (1.105--1.336)   \<0.001
  Distant metastasis   \<0.001      0.667 (0.508--0.875)   0.004
  AJCC stage           \<0.001      2.087 (1.698--2.566)   \<0.001
  Radicality           \<0.001      2.140 (1.860--2.463)   \<0.001
  Tumor size (cm)      \<0.001      1.311 (1.164--1.476)   \<0.001
  Tumor location       \<0.001      0.958 (0.899--1.020)   0.180
  MLNR                 \<0.001      1.295 (1.104--1.519)   0.001
  Differentiation      \<0.001      1.188 (1.018--1.385)   0.029
  Ascites              \<0.001      1.241 (0.965--1.595)   0.092
  CA19--9 (µ/mL)       \<0.001      1.218 (1.076--1.378)   0.002
  CEA (ng/mL)          \<0.001      1.182 (1.045--1.336)   0.008
  Hb (g/L)             \<0.001      1.004 (0.892--1.130)   0.944
  Tobacco              0.376                               
  dNLR                 \<0.001      1.202 (1.007--1.435)   0.042
  MLR                  \<0.001      1.156 (1.023--1.305)   0.020
  NLR                  \<0.001      0.861 (0.714--1.039)   0.119
  PLR                  \<0.001      0.933 (0.820--1.062)   0.291
  PNI                  \<0.001      0.951 (0.842--1.075)   0.423

**Abbreviations:** AJCC, American Joint Committee on Cancer; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; dNLR, derived neutrophil to lymphocyte ratio; Hb, hemoglobin; HR, hazard ratio; MLNR, metastatic lymph node ratio. MLR, monocyte to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PNI, prognostic nutritional index.
